Genentech reveals survival data for MPDL3280A in NSCLC
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) announced interim results from the Phase II POPLAR study comparing anti- PD-L1 antibody MPDL3280A with docetaxel in squamous and non-squamous non-small cell lung cancer (NSCLC). Patients in the trial with higher levels of PD-L1 expression showed longer overall survival (OS) and progression-free survival (PFS) than those with lower or no expression. Genentech expects to present the results at the American Society of Clinical Oncology Meeting in Chicago.
The 287-patient study stratified previously treated NSCLC patients into four groups based on PD-L1 expression, including a group for non-expressors. Median OS, the study's primary endpoint, was not reached among patients receiving MPDL3280A in the highest-expressing group, while those receiving docetaxel had a median OS of 11.1 months (HR=0.47, 95% CI: 0.20, 1.11). Among the top two groups of expressors combined, the MPDL3280A arm had a median OS of 13 months vs. 7.4 months in docetaxel patients (HR=0.56, 95% CI: 0.33, 0.95). Among patients who did not express PD-L1, both MPDL3280A and docetaxel produced a median OS of 9.7 months (HR=1.22, 95% CI: 0.69, 2.14). ...